PTLD-1: response to rituximab induction as a predictive marker allowing stratification into rituximab or R-CHOP consolidation in B-cell post-transplant lymphoproliferative disorder

International prospective phase 2 trial of risk-stratified sequential treatment in CD20-positive post-transplant lymphoproliferative disorder after solid organ transplantation: four weekly rituximab infusions, then four further rituximab doses for patients in complete remission or four cycles of R-CHOP for all others.

111 of 126 patients responded (88 percent), 88 with a complete response (70 percent); the three-year response duration estimate was 82 percent and median overall survival 6.6 years. Grade 3 or 4 infections occurred in 34 percent and treatment-related mortality was 8 percent. Response to rituximab induction remained prognostic for survival.